Because scope 3 covers the entire value chain, pharma scientists should integrate sustainability into R&D, manufacturing, and ...

End-to-end CDMO services simplify drug development for small biopharma companies, reducing complexity, time, and costs while ...

Kimberly‑Clark said on Nov. 3, 2025 that it is planning to acquire Kenvue, the former Johnson & Johnson unit and maker of ...

The Critical Medicines Act (CMA) addresses supply chain vulnerabilities by redefining procurement criteria, emphasizing quality, security, and environmental standards. European manufacturers gain ...

Darrin Lang is CEO, LABUR. Larry Egan is Vice President of Strategic Technologies, Alnylam Pharmaceuticals Inc.

In this episode of Drug Digest, the discussion centers around the optimization of biopharmaceutical manufacturing and supply chain efficiency through the mastering of AI capabilities, data integration ...

In the first part of this interview, Romanski tells PharmTech Group that while the field of oral dosage forms has not grown ...

In this PharmTech video feature, we highlight the week’s industry news in an easy-to-consume, fun format. New roundups will ...

As a part of its CPHI Frankfurt 2025 coverage, Pharmaceutical Technology ® interviewed Sriman Banerjee, PhD, executive ...

Localized supply chains are crucial for mitigating geopolitical risks and ensuring operational continuity in the biopharmaceutical sector. Regulatory harmonization enhances access to medicines, ...

J.D. Mowery, Bora, says tariffs localize biopharma supply chains, the "biotech freeze" mandates robust data, and AI rapidly ...

Maggie Saykali, Cefic, explains that Western pharma vulnerability stems from market loss to Asia, caused largely by ...